- Home
- WU vs RCUS Comparison
WU vs RCUS Comparison
Compare WU & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | RCUS |
|---|---|---|
| Founded | 1851 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WU | RCUS |
|---|---|---|
| Price | $8.16 | $23.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $9.00 | ★ $31.90 |
| AVG Volume (30 Days) | ★ 6.6M | 798.2K |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $4,050,700,000.00 | $247,000,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $4.73 | $45.62 |
| P/E Ratio | $40.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.85 | $7.92 |
| 52 Week High | $10.35 | $28.72 |
Technical Indicators
Market Signals| Indicator | WU | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 46.77 |
| Support Level | $7.96 | $22.61 |
| Resistance Level | $8.34 | $24.33 |
| Average True Range (ATR) | 0.25 | 1.05 |
| MACD | -0.04 | -0.17 |
| Stochastic Oscillator | 9.09 | 32.81 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2025 and is the largest money transfer company in the world.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.